{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Hb Above 1 g/dL of Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Hb Maintained Within ± 1 g/dL of Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hb Below 1 g/dL of Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Hb Above 12 g/dL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Hb Maintained Within 10-12 g/dL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hb Below 10 g/dL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Number of participants with an average Hb concentration during the evaluation period within ± 1 g/dL of their baseline Hb is reported as well as the number of participants with an average Hb concentration above, within or below the range of 10-12 g/dL. The evaluation period was defined as the period between Week 17 and Week 21 inclusive.","groups":[{"description":"Mircera was administered subcutaneously once every 4 weeks.","id":"OG000","title":"Mircera"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants enrolled in the study. Hb values within 21 days after blood transfusion(s) were excluded from analysis. Number analyzed is the number of participants with Hb concentration assessment at specified time points.","reportingStatus":"POSTED","timeFrame":"Week 17 up to Week 21","title":"Number of Participants With an Average Hb Concentration During the Evaluation Period Within ± 1 g/dL of Their Baseline Hb and Above, Within or Below the Range of 10-12 g/dL","type":"SECONDARY","unitOfMeasure":"participants"}